CRDF
What one share of Cardiff Oncology holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care ("SoC") therapeutics.
Cardiff Oncology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.59 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.60 |
| Cash and investments | $0.13 |
| Book value | $0.39 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.08 | −$8.23 | $0.16 | −$6.31 | — | $3.86 |
| 2017 | $1.05 | −$51.76 | $0.21 | −$48.54 | — | $8.87 |
| 2018 | $0.16 | −$8.26 | $0.00 | −$5.67 | — | $2.63 |
| 2019 | $0.04 | −$2.80 | $0.01 | −$2.23 | — | $0.85 |
| 2020 | $0.02 | −$1.08 | $0.01 | −$0.79 | — | $3.48 |
| 2021 | $0.01 | −$0.73 | $0.01 | −$0.60 | — | $3.35 |
| 2022 | $0.01 | −$0.89 | $0.02 | −$0.80 | — | $2.38 |
| 2023 | $0.01 | −$0.93 | $0.01 | −$0.70 | — | $1.56 |
| 2024 | $0.01 | −$0.95 | $0.00 | −$0.79 | — | $1.25 |
| 2025 | $0.01 | −$0.69 | $0.00 | −$0.57 | — | $0.66 |